Teicoplanin therapy leading to a significant decrease in viral load in a patient with chronic hepatitis C.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Repositioning of Antibiotics in the Treatment of Viral Infections.Current microbiology · 2024
   Review
2. Battling COVID-19: using old weapons for a new enemy.Tropical diseases, travel medicine and vaccines · 2020
   Review
3. Glycopeptides as Potential Interventions for COVID-19.Biologics : targets & therapy · 2020
   Review
4. COVID-19 Therapeutic Options Under Investigation.Frontiers in pharmacology · 2020
   Review
5. A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics.MedChemComm · 2017
   Review
6. Fighting viruses with antibiotics: an overlooked path.International journal of antimicrobial agents · 2016
   Article
7. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV).The Journal of biological chemistry · 2016
   Article
8. Teicoplanin inhibits Ebola pseudovirus infection in cell culture.Antiviral research · 2016
   Article
9. Rational selection and engineering of exogenous principal sigma factor (σ(HrdB)) to increase teicoplanin production in an industrial strain of Actinoplanes teichomyceticus.Microbial cell factories · 2014
   Article

Corrections and comments

• Comment on
  Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics.2011

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as